Related references
Note: Only part of the references are listed.Epidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non-Small-Cell Lung Cancer
Shigehiro Yagishita et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small-Cell Lung Cancer Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)
Rogerio Lilenbaum et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley et al.
LANCET ONCOLOGY (2015)
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B. Besse et al.
ANNALS OF ONCOLOGY (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer
Sivan M. Bokobza et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer
Puneeth Iyengar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
Siow Ming Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Dong-Yeop Shin et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Radiation Pneumonitis in Patients with Non-Small-Cell Lung Cancer Treated with Erlotinib Concurrent with Thoracic Radiotherapy
Hongqing Zhuang et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Epidermal growth factor receptor mutations in lung adenocarcinoma
Markus D. Siegelin et al.
LABORATORY INVESTIGATION (2014)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. Vansteenkiste et al.
ANNALS OF ONCOLOGY (2013)
Clinical Observation of Whole Brain Radiotherapy Concomitant with Targeted Therapy for Brain Metastasis in Non-small Cell Lung Cancer Patients with Chemotherapy Failure
Yong Cai et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer
James W. Welsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Justin F. Gainor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Helena A. Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer
Ramon Andrade de Mello et al.
PHARMACOGENOMICS (2013)
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
Hongqing Zhuang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)
S. Niho et al.
ANNALS OF ONCOLOGY (2012)
Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study
Yin-Duo Zeng et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Gianfranco A. Pesce et al.
EUROPEAN JOURNAL OF CANCER (2012)
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer
Andrew J. Weickhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
GEFITINIB IN COMBINATION WITH IRRADIATION WITH OR WITHOUT CISPLATIN IN PATIENTS WITH INOPERABLE STAGE III NON SMALL CELL LUNG CANCER: A PHASE I TRIAL
Sacha Rothschild et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
PROSPECTIVE STUDY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS CONCURRENT WITH INDIVIDUALIZED RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Jing Wang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience
Chih-Chia Chang et al.
LUNG CANCER (2011)
Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
Takehito Shukuya et al.
LUNG CANCER (2011)
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
Isamu Okamoto et al.
LUNG CANCER (2011)
Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC
Raymond H. Mak et al.
ONCOLOGIST (2011)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
Anne Auperin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and Maintenance Gefitinib for Patients with Stage III Non-small Cell Lung Cancer
Brian Center et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial
Neal Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Unexpected High Lung Toxicity from Radiation Pneumonitis in a Phase I/II Trial of Concurrent Erlotinib with Limited Field Radiation for Intermediate Prognosis Patients with Stage III or Inoperable Stage IIB Non-small-cell Lung Cancer(NSCLC)
J. Wan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population
Shenglin Ma et al.
LUNG CANCER (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer
Akash Nanda et al.
CLINICAL LUNG CANCER (2008)
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer
Nicholas W. Choong et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer
Thomas E. Stinchcombe et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma
Amit K. Das et al.
CANCER RESEARCH (2007)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
M Baumann et al.
RADIOTHERAPY AND ONCOLOGY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Review of epidermal growth factor receptor biology
RS Herbst
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
